Fast-growing CRO uses Veeva Vault Clinical Suite to substantially reduce startup time
NEW PROVIDENCE, N.J. and BARCELONA, Spain, May 30, 2023 /PRNewswire/ — Veeva Systems (NYSE: VEEV) today announced that Lotus Clinical Research has expanded its partnership with Veeva and expanded its adoption of the Veeva Vault Clinical Suite, a strategic move to strengthen its service delivery and efficiency. This builds on Lotus’ existing use of the Vault Clinical Suite to implement faster, more connected studies. The successful addition of Veeva Vault CDMS, Veeva Vault eTMF, and Veeva Vault CTMS has effectively scaled Lotus test operations while maintaining the highest quality standards. With a unified clinical ecosystem, Lotus has significantly reduced study initiation time.
Lotus President Bill Martin explained the benefits of the partnership with Veeva: “This collaboration enables Lotus to conduct a higher volume of clinical trials while improving coordination with sponsors and clinical trial sites. The integrated clinical applications and ease of use are vital to Lotus as we continue to diversify our disease expertise and increase our site interactions and patient recruitment.”
As a rapidly expanding CRO, Lotus sought to develop an adaptable, connected, and scalable infrastructure to keep pace with its growth. The in-house team of trained programmers now leverages Vault CDMS, its primary clinical data management system, to design studies completely in-house. This has resulted in faster delivery of electronic data capture (EDC) study compilations, significantly reducing study initiation time.
Using integrated applications on a single platform has allowed Lotus to effortlessly share questionnaires and metrics between Vault CDMS and Vault CTMS, simplifying tracking reporting. With a single source of documentation and a seamless flow of data and documents across clinical applications, Lotus can increase compliance, ensure rapid study initiation, and provide a better on-site experience. These advances have fueled Lotus’ transition from a company with an initial focus on acute pain and the CNS to one that supports all facets of clinical research.
“We are proud to grow our partnership of more than five years with Lotus, bringing together their experience and insight in running complex clinical trials with our technology expertise,” said Jon Young, Chief Strategy Officer, Veeva Vault Clinical. “With Veeva Vault Clinical Suite, Lotus is able to provide value-added services to customers and optimize the way they work with sites for greater speed and agility.”
About Lotus Clinical Research Lotus is a scientifically driven, full-service, consultative CRO, providing services in all phases of clinical development with a heritage and focus on CNS research. Since its inception in 2001, Lotus has strategically focused the growth of its services, experience and regulatory knowledge to successfully partner with biopharmaceutical companies to execute clinical trials in all indications from Phase 1 to 4.
Lotus is unique compared to other CROs because they are owned by Emerge Holdco, LLC, which also owns Evolution Research Group, LLC (ERG), a leading clinical site organization with more than 20 wholly owned clinical research sites in the US. USA, with more than 450 beds, conducting complex early and late phase trials in both healthy volunteers and highly specialized diverse populations. The successful conduct of clinical trials at Lotus is the result of therapeutic expertise and the highest level of talent in medical, operational and support functions. For more information visit lotuscr.com.
About Veeva Systems Veeva is the world leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, from the world’s largest pharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva’s Forward-Looking Statements This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we are under no obligation to update such statements. There are numerous risks that could adversely affect our results, including the risks and uncertainties disclosed in our Form 10-K filing for the fiscal year ended January 31, 2023, which you can find here (pages 9 and 10 contain a summary of risks that may affect our business), and in our subsequent filings with the SEC, which can be accessed at sec.gov.
Logo – https://mma.prnewswire.com/media/1488285…
View original content: https://www.prnewswire.com/news-releases/lotus-clinical-research-amplia-la-asociacion-con-veeva-para-acelerar-los-ensayos-clinicos-301836678.html
